Dinesh V. Patel, Ph.D., is a distinguished leader in the biopharmaceutical industry, currently serving as the President and Chief Executive Officer at Protagonist Therapeutics Inc. Dr. Patel has a robust background in drug discovery and development, with over three decades of experience in the field. Before joining Protagonist Therapeutics, he held significant roles at major pharmaceutical companies, including Senior Vice President of Drug Discovery at Theravance Biopharma and Vice President of Chemistry at Celera Genomics. His career also includes notable tenures at Bristol-Myers Squibb and Syntex/Roche, where he contributed to the development of several successful drug candidates. At Protagonist Therapeutics, Dr. Patel has been instrumental in steering the company towards its mission of developing innovative peptide-based drugs for serious diseases. Under his leadership, the company has advanced its pipeline, notably with the development of rusfertide, a potential treatment for polycythemia vera, and JNJ-2113, a collaboration with Johnson & Johnson for inflammatory bowel disease. Dr. Patel's strategic vision and scientific expertise have been pivotal in securing key partnerships and advancing clinical trials, positioning Protagonist Therapeutics as a leader in the peptide therapeutics space. Dr. Patel's contributions to the field extend beyond his corporate roles. He is an inventor on numerous patents and has authored several scientific publications, reflecting his commitment to advancing medical science. His leadership style emphasizes innovation, collaboration, and patient-centric approaches, which have been crucial in driving Protagonist Therapeutics' growth and success. Dr. Patel's dedication to transforming the lives of patients through groundbreaking therapies continues to inspire his team and the broader biopharmaceutical community.